An observational study in Biliary Tract Cancer (BTC), Biliary Tract Cancer (CCA) and Cholangiocarcinoma, sponsored by University of Nottingham. Recruiting at 1 site in United Kingdom. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-04-29.
Sponsored by University of Nottingham · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Biliary Tract Neoplasms with a site in United Kingdom — 11 open to participants now, 19 under way, 6 of them phase 3. Biliary Tract Neoplasms · United Kingdom.
Among the 42 studies in Biliary Tract Neoplasms with a site in United Kingdom, this one is the only one that started in 2026, is one of 4 observational ones, reaches primary completion later than 14 of the 18 other live ones, and was the 40th registered.
521 studies on the registry are indexed under Biliary Tract Neoplasms; 201 are open to participants now.
Browse Biliary Tract Neoplasms studies →11 of the 42 studies in Biliary Tract Neoplasms with a site in United Kingdom are open now. Recruiting first, the newest first:
AstraZeneca · Sites in United Kingdom, United States, Australia and 16 more countries
Ages 18+
UNICANCER · Sites in United Kingdom, France
Ages 18+
Royal Marsden NHS Foundation Trust · Sites in United Kingdom
Ages 18+
AstraZeneca · Sites in United Kingdom, United States, Australia and 24 more countries
Ages 18–99
Jazz Pharmaceuticals · Sites in United Kingdom, United States, Argentina and 22 more countries
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 142 Biliary Tract Neoplasms studies recruiting now, 82 (58%) set no upper age limit and 37 (26%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 23 · Phase 3 11
First in 2004; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 160 is close to the median of 160 across 73 observational studies indexed under Biliary Tract Neoplasms.
Median enrollment 217 across the 37 interventional studies, 150 across the 4 observational. Of the 20 that completed or were terminated, 12 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 42 have an industry lead sponsor. The 10 most frequent:
University of Nottingham is the lead sponsor of 465 studies on the registry; 80 are open to participants now.
University of Nottingham has 1 study filed under Biliary Tract Neoplasms — fewer than ten, so there is no comparison to draw.
7 of the studies in Biliary Tract Neoplasms with a site in United Kingdom that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05615818Phase 3UNICANCERPersonalized Medicine for Advanced Biliary Cancer Patients | 2027-06 |
| NCT05094336AmgenA Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101) | 2026-11-30 |
| NCT07673861Royal Marsden NHS Foundation TrustClinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer Patients | 2026-12-31 |
| NCT06921928AstraZenecaStudy for AZD4360 in Participants With Advanced Solid Tumours | 2027-03-31 |
| NCT04644068AstraZenecaStudy of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies | 2027-05-28 |
Add all 7 to your calendar (.ics) → With an account.
Among the 42 studies in Biliary Tract Neoplasms with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Hepato-Pancreato-Biliary (HPB) cancers originating in the liver, bile ducts, pancreas, and gall bladder represent a rising global health challenge, with incidence doubling in the UK over the past decade. Cholangiocarcinoma (CCA) and pancreatic cancer are particularly aggressive, often detected late due to non-specific symptoms and difficulties in sampling or imaging. In the UK, CCA affects around 3,000 people annually, with only 13% surviving 3 years, while pancreatic cancer has a 5-year survival of 8.3%. Diagnosis is complicated by the anatomical narrowness of the bile duct and the similarity between malignant and benign strictures. Standard imaging often cannot distinguish between inflammation and cancer, while tissue sampling is challenging, paucicellular, and limited in sensitivity, necessitating repeated biopsies. Yet, accurate characterisation is critical as NICE now recommends targeted therapies (FGFR2, NTRK, MSI-H/dMMR, IDH1 mutations) that require molecular profiling.
Both CCA and PDAC display high heterogeneity, further complicating treatment. Emerging approaches such as Raman spectroscopy can map malignant tissues by detecting vibrational energy shifts, but require further validation due to weak signals. For focal or cystic HPB lesions not well visualised by conventional imaging, novel modalities like ultra-thin endoscopes with scattering/absorption imaging are being developed for improved early diagnosis.
Management of biliary obstruction frequently involves stenting to restore bile flow, essential for palliation and pre-treatment optimization. However, stent failure from tumour ingrowth, displacement, or erosion remains common, and evidence for best stent use is limited. Novel approaches, including drug-eluting coatings and nanoparticle-mediated wireless treatment delivery, are being investigated.
To overcome diagnostic and therapeutic barriers, flexible snake-like robotic systems with navigation, sampling, spectroscopy, and treatment capabilities are being developed. These devices, alongside ultra-thin endoscopes and integrated Raman spectroscopy, aim to characterise strictures, generate 3D imaging in ex-vivo HPB tissue, and permit targeted ablation. Parallel work will explore molecular and fluid-based biomarkers (blood, bile, cyst fluid) to support minimally invasive diagnosis and monitoring.
Through integration of engineering, molecular diagnostics, and device innovation, this transdisciplinary research programme (UKRI and MRC funded) seeks to transform early detection, accurate diagnosis, and novel treatment of HPB cancers, thereby improving outcomes in CCA, pancreatic malignancy, and other clinically similar biliary disorders.
Aim:
To provide a detailed understanding of the characteristics (including clinical and molecular) of liver and pancreatic biliary focal lesions (inflammatory and cancerous) and create a bioresource of liver, pancreas, gallbladder and biliary tract associated tissue and fluids (biopsies, brushings, resected tissues, bile and cyst fluid and blood samples) in order to develop innovative tools for accurate diagnosis and treatment.
Study Configuration: Prospective Longitudinal Cohort study Setting: Secondary care centre, Nottingham University Hospitals NHS Trust. (NUH).
Co-ordinated by the NIHR Nottingham Biomedical Research Centre Description of interventions: This is an observational study involving collecting tissue or body fluids (such as bile or pancreatic cyst fluid) during clinical care in addition to collection of blood samples (for DNA, serum and plasma) and data collection.
Surplus tissue residual to the requirements for standard care will be stored and used. Additional tissue samples and body fluid samples collected for research at time of clinical investigations will not be increasing the risk of the clinical procedure.
Blood samples will be collected from patients at the time of enrolment in the study. These may be collected before and/ or after diagnosis is secured.
Duration of study: Overall duration: 60 months Outcome measures: - To report the proportion of patients where adequate tissue could be retrieved from HPB biopsy to come to definitive diagnosis using standard of care.
Patients undergoing investigations for the diagnosis and treatment of a HPB focal lesions Patients undergoing surgical resection (of liver, pancreas, gallbladder or bile duct)
Inclusion Criteria:
Patients attending Nottingham University Hospitals NHS Trust (NUH) as part of standard clinical care for either:
Exclusion Criteria: No exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
(a) (up to 140 cases) Patients undergoing investigations for the diagnosis and treatment of a HPB focal lesions (in the liver, gall bladder, bile duct, biliary tract or pancreas), including stricture and pancreatic cysts. Investigations will be determined and performed as a part of the standard of care. (The type of investigations varies and is decided by the clinician in charge or multidisciplinary team meeting decision.) These will be performed using either endoscopic or radiologic approaches including: * Endoscopic Ultrasound (EUS) with endoscopic fine needle acquisition of tissue (FNA/FNB/cyst wall biopsy) for pancreatic cysts or any pancreatic lesion, Endoscopic retrograde cholangio-pancreatography (ERCP) and/or cholangioscopy (SpyGlass™ device) for liver or biliary strictures. * Percutaneous sampling of liver or biliary strictures using ultrasound or percutaneous transhepatic cholangiography (PTC) and/or SpyGlass Discover™ cholangioscopy.
(up to 20 cases) Patients undergoing surgical resection (of liver, pancreas, gallbladder or bile duct) as standard of care for any underlying condition.
To characterise biliary strictures and hepato-pancreato-biliary (HPB) focal lesions
To characterise biliary strictures and hepato-pancreato-biliary (HPB) focal lesions to diagnose cancers including cholangiocarcinoma (CCA) in a prospective patient cohort, establishing clinical features (manifestations, pathology, cytology, treatment responses and outcomes) and molecular, cellular, structural and physical properties.
Time frame: 3 years
To create a database and associated bioresource of HPB tissues
To create a database and associated bioresource of HPB tissues (, including the liver, bile duct, gallbladder and pancreas), with or without any focal lesion, for analysis of diagnostic and treatment technologies under development in the laboratory (super-slender robot, ultra-thin scattering absorption and shape endoscope, and electrical actuation technology).
Time frame: 3 years
To develop a library of images
To develop a library of images (Endoscopic, Radiology, Raman Spectroscopy) of biliary strictures and HPB lesions or HPB resected tissue linked to specific cyto/ histology and molecular information.
Time frame: 3 years
To correlate Raman Spectroscopic images
To correlate Raman Spectroscopic images with molecular characteristics of the HPB samples.
Time frame: 3 years
To identify genetic markers and biomarkers for early diagnosis
To identify genetic markers and biomarkers for early diagnosis and monitoring of HPB lesions.
Time frame: 3 years
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Sep 2028, 32 months after the start.
Of 44 observational studies under Biliary Tract Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 132. This study's planned 32 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.